Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

Innovative approach using KITE-439 in targeting HPV-related malignancies

August 20, 2019 | City of Hope

HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.

ET140202 Artemis T Cell therapy for the treatment of liver cancer

August 20, 2019 | City of Hope

City of Hope is the first institution in the United States to open an immunotherapy clinical trial for liver cancer that eventually could transform treatment of the usually fatal disease into an outpatient procedure.

City of hope's bone marrow transplant program reaches two historic milestones

February 26, 2019 | City of Hope

City of Hope’s bone marrow transplant has played a crucial role in the advancement of the procedure that it began doing more than four decades ago.

Researcher's Ovarian Cancer Discovery Takes on Special Meaning

June 27, 2018 | City of Hope

The results of a study published earlier this year by TGen researchers (City of Hope affiliate) in the journal Clinical Cancer Research suggest an existing leukemia drug, ponatinib, shows promise against SCCOHT.

City of Hope Guides ASCO’s New Geriatric Cancer Recommendations

June 8, 2018 | Saundra Young

City of Hope physicians Arti Hurria, M.D., a geriatric oncologist, and William Dale, M.D., Ph.D., a geriatrician and palliative care physician, co-chaired the panel that developed the new ASCO guidelines designed to help doctors assess and manage care for older adults.

City of Hope Researchers Publish First Report on a Protein Inhibitor for Advanced Bladder Cancer

June 8, 2018 | Letisia Marquez

Advanced bladder cancer is particularly difficult to treat. The five-year survival rate for Stage 4 bladder cancer is only about 15 percent. Now, City of Hope researchers have discovered a that a novel drug blocks a key protein that drives the disease.

City of Hope to offer CAR T cell therapy for patients with the most common type of NHL

May 4, 2018 | Letisia Marquez

City of Hope recently announced that it is one of the first treatment centers certified in the United States to administer tisagenlecleucel CAR T cell therapy to adult patients with relapsed or refractory large B cell lymphoma.

City of Hope to provide first FDA-approved CAR T cell therapy for some patients with ALL

April 13, 2018 | City of Hope

City of Hope recently announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration – to patients.